R&D World: Mayo Clinic backs ViewsML in $4.9M round to advance virtual biomarker staining

Coverage
Written By ViewsML

Our CEO, Kenneth To, recently spoke with Brian K. Buntz of R&D World about how AI is transforming digital pathology by unlocking clinically meaningful insights from routine H&E tissue images within existing workflows.

The conversation explores how ViewsML is helping biopharma organizations maximize the value of existing tissue samples through virtual biomarker staining, enabling researchers to generate richer biomarker insights without consuming additional tissue, and accelerating patient selection and enrollment for clinical trials.

Kenneth also discusses:

  • Our recent $4.9 million funding round, which welcomed Mayo Clinic as a new investor.

  • Our first-of-its-kind virtual biomarker library.

  • The advantage of our virtual multiplexing, which provides deeper spatial biology insights by computationally layering multiple biomarkers.

Read the full interview: https://www.rdworldonline.com/mayo-clinic-backs-viewsml-in-4-9m-round-to-advance-virtual-biomarker-staining/

ViewsML
Previous

ViewsML’s AI-Powered Virtual Biomarker Staining Research to be Presented at American Association for Cancer Research Drug Discovery and Development Conference 2026 (AACR D3)
Next

The Pathologist: Virtual Staining and the Next Era of Pathology